Murine studies suggest that aortic-root dilation in Marfan's syndrome is due to excessive signaling by transforming growth factor {beta** (TGF-{beta**) and can be mitigated by TGF-{beta** antagonists, such as angiotensin II-receptor blockers (ARBs). This study reviewed data on 18 pediatric patients with Marfan's syndrome who had begun ARB therapy and had been followed for at least 12 months. The rate of increase in aortic-root diameter was significantly slowed after the initiation of ARB therapy.
More...